Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Arcutis Biotherapeutics

05/08/2026 22:39

Arcutis Biotherapeutics, Inc. ARQT.OQ reported quarterly adjusted earnings of 11 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -13 cents.  The mean expectation of eight analysts for the quarter was for earnings of 4 cents per share. Wall Street expected results to range from zero cents to 13 cents per share.
Revenue rose 59.3% to $129.86 million from a year ago; analysts expected $118.85 million. 
Arcutis Biotherapeutics, Inc.'s reported EPS for the quarter was 11 cents​.
The company reported quarterly net income of $15.01 million.
Arcutis Biotherapeutics, Inc. shares had fallen by 0.7% this quarter and lost 10.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 40.7% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Arcutis Biotherapeutics, Inc. is $35.00, about 25.6% above its last closing price of $26.03
This summary was machine generated from LSEG data August 5 at 09:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.04
0.11
Beat
Mar. 31 2026 
-0.08
-0.09
Missed
Dec. 31 2025 
0.11
0.13
Beat
Sep. 30 2025 
-0.10
0.06
Beat